149 related articles for article (PubMed ID: 29881288)
21. siRNA-mediated stathmin1 silencing inhibits proliferation of prostate carcinoma cell line.
Aksoy A; Göktürk S; Etem Önalan E; Tektemur A; Artaş G; Varoğlu A; Koç M
Turk J Biol; 2022; 46(3):239-250. PubMed ID: 37529254
[TBL] [Abstract][Full Text] [Related]
22. SRPX2 and RAB31 are effective prognostic biomarkers in pancreatic cancer.
Li H; Zhang SR; Xu HX; Wang WQ; Li S; Li TJ; Ni QX; Yu XJ; Liu L; Wu CT
J Cancer; 2019; 10(12):2670-2678. PubMed ID: 31258775
[No Abstract] [Full Text] [Related]
23. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of SFRP1 as a favorable predictive and prognostic biomarker in patients with prostate cancer.
Zheng L; Sun D; Fan W; Zhang Z; Li Q; Jiang T
PLoS One; 2015; 10(2):e0118276. PubMed ID: 25719802
[TBL] [Abstract][Full Text] [Related]
25. N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Wu Q; Xie X; Huang Y; Meng S; Li Y; Wang H; Hu Y
J Cancer; 2021; 12(3):682-692. PubMed ID: 33403026
[TBL] [Abstract][Full Text] [Related]
26. Sushi repeat-containing protein X-linked 2: A novel phylogenetically conserved hypothalamo-pituitary protein.
Anwer M; Bolkvadze T; Ndode-Ekane XE; Puhakka N; Rauramaa T; Leinonen V; van Vliet EA; Swaab DF; Haapasalo A; Leskelä S; Bister N; Malm T; Carlson S; Aronica E; Pitkänen A
J Comp Neurol; 2018 Aug; 526(11):1806-1819. PubMed ID: 29663392
[TBL] [Abstract][Full Text] [Related]
27. The cell cycle gene centromere protein K (
Chen X; Shao Y; Li Y; Yang Z; Chen Y; Yu W; Shang Z; Wei W
Transl Cancer Res; 2022 May; 11(5):1099-1111. PubMed ID: 35706799
[TBL] [Abstract][Full Text] [Related]
28. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
29. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.
Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M
Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the expression and association of retinoblastoma binding protein 6 with the JNK signaling pathway in prostate cancers.
Guan WY; Zhao S; Luo YN
Cell Biol Int; 2020 Oct; 44(10):2107-2119. PubMed ID: 32662898
[TBL] [Abstract][Full Text] [Related]
32. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
33. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
[TBL] [Abstract][Full Text] [Related]
34. SRPX2 promotes cell migration and invasion via FAK dependent pathway in pancreatic cancer.
Gao Z; Zhang J; Bi M; Han X; Han Z; Wang H; Ou Y
Int J Clin Exp Pathol; 2015; 8(5):4791-8. PubMed ID: 26191169
[TBL] [Abstract][Full Text] [Related]
35. High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.
Zhang Z; Xie H; Zhu S; Chen X; Yu J; Shen T; Li X; Shang Z; Niu Y
Med Sci Monit; 2018 Nov; 24():8190-8197. PubMed ID: 30427826
[TBL] [Abstract][Full Text] [Related]
36. Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer.
Jiang D; Xiao C; Xian T; Wang L; Mao Y; Zhang J; Pang J
Onco Targets Ther; 2018; 11():1077-1086. PubMed ID: 29535532
[TBL] [Abstract][Full Text] [Related]
37. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
38. Reduced expression of PinX1 correlates to progressive features in patients with prostate cancer.
Shi R; Zhao Z; Zhou H; Wei M; Ma WL; Zhou JY; Tan WL
Cancer Cell Int; 2014; 14():46. PubMed ID: 24936151
[TBL] [Abstract][Full Text] [Related]
39. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
